SCHEMBL3407239

SCHEMBL3407239

Cc1ccccc1CC1(N(C)C)CCC(NC(=O)COCCN(C)S(=O)(=O)c2ccc(Cl)cc2Cl)CC1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.37
LMNA P02545 5/20 0.37
HPGD P15428 1/20 0.37
MAPT P10636 2/20 0.36
ALDH1A1 P00352 5/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MCHR1 Q99705 1/20 0.36
BDKRB1 P46663 4/20 0.35
KMT2A Q03164 3/20 0.35
GAA P10253 2/20 0.35
MEN1 O00255 2/20 0.35
PKM P14618 1/20 0.35
TSHR P16473 1/20 0.35
POLB P06746 1/20 0.34
RAB9A P51151 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3409729 0.85 MCHR1 (0.38) LMNAMAPTALDH1A1MCHR1BDKRB1
SCHEMBL3410210 0.83 BDKRB1 (0.53) BDKRB1
SCHEMBL3408492 0.80 MCHR1 (0.39) SMN1; SMN2LMNAALDH1A1MCHR1BDKRB1
SCHEMBL3412648 0.79 BDKRB1 (0.38) SMN1; SMN2LMNAALDH1A1MCHR1BDKRB1
SCHEMBL3410955 0.79 OPRM1 (0.39) MAPTALDH1A1BDKRB1RAB9A
SCHEMBL492458 0.77 MAPT (0.38) SMN1; SMN2LMNAHPGDMAPTALDH1A1
SCHEMBL2989096 0.76 ATF4 (0.58) SMN1; SMN2LMNAHPGDALDH1A1HTT
SCHEMBL3409948 0.76 BDKRB1 (0.38) LMNAALDH1A1HTTMCHR1BDKRB1
SCHEMBL2974336 0.75 MEN1 (0.46) HPGDALDH1A1NPSR1KMT2AGAA
SCHEMBL493216 0.75 CACNA2D1 (0.43) MAPTMCHR1BDKRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257527-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-12-08 EP claimed
US-20090253669-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-10-08 US claimed
WO-2009115257-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2009-09-24 WO claimed
EP-2257527-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-12-08 EP disclosed
US-20090253669-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-10-08 US disclosed
WO-2009115257-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253669-A1 Substituted Sulfonamide Compounds SULT2A1, STS, SULT1A1 SMN1; SMN2 824/4885LMNA 2546/4885HPGD 1485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.